McInnes, N., Smith, A., Otto, R., Vandermey, J., Punthakee, Z., Sherifali, D., … Gerstein, H. C. (2017, March 15). Piloting a remission strategy in type 2 diabetes: Results of a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism, 2016-3373. Retrieved from https://academic.oup.com/jcem/article-abstract/doi/10.1210/jc.2016-3373/3070517/Piloting-a-Remission-Strategy-in-Type-2-Diabetes?redirectedFrom=fulltext
Connection itself can be monetized, of course—in ways that create factions and cliques, or in inclusive ways that bring together people of various socioeconomic strata. That actually may look something like Wanderlust. The market is flooded with things we can consume alone on our couches or at the gym with headphones in. But we are hungry for connection—to hear the same things said but to have a person speaking directly to us (and to a few hundred other people).
"Secondary" diabetes refers to elevated blood sugar levels from another medical condition. Secondary diabetes may develop when the pancreatic tissue responsible for the production of insulin is destroyed by disease, such as chronic pancreatitis (inflammation of the pancreas by toxins like excessive alcohol), trauma, or surgical removal of the pancreas.
Studies in type 1 patients have shown that in intensively treated patients, diabetic eye disease decreased by 76%, kidney disease decreased by 54%, and nerve disease decreased by 60%. More recently the EDIC trial has shown that type 1 diabetes is also associated with increased heart disease, similar to type 2 diabetes. However, the price for aggressive blood sugar control is a two to three fold increase in the incidence of abnormally low blood sugar levels (caused by the diabetes medications). For this reason, tight control of diabetes to achieve glucose levels between 70 to120 mg/dl is not recommended for children under 13 years of age, patients with severe recurrent hypoglycemia, patients unaware of their hypoglycemia, and patients with far advanced diabetes complications. To achieve optimal glucose control without an undue risk of abnormally lowering blood sugar levels, patients with type 1 diabetes must monitor their blood glucose at least four times a day and administer insulin at least three times per day. In patients with type 2 diabetes, aggressive blood sugar control has similar beneficial effects on the eyes, kidneys, nerves and blood vessels.
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
Lab studies show that Encellin’s “ultra thin-film implantable cell delivery system” keeps islet cells alive and functioning. In a 2015 study in the journal ACS Nano, Dr. Nyitray and others found that cells in the packaging survived for 90 days in lab animals. New blood vessels grew around the transplants and the cells produced insulin in response to rising glucose levels. In a 2016 study from Dr. Desai’s lab, also published in ACS Nano, human islet cells packaged in the tiny film envelopes survived for six months in mice—and the cells made and released insulin in response to rising blood glucose levels.
Stream a variety of exercise routines to get you moving and motivated! GlucoseZone™ is a digital exercise program that provides you with personalized exercise guidance and support designed to help you achieve the diabetes and fitness results you want. American Diabetes Association members receive an exclusive discount on their GlucoseZone subscription when they sign up using their ADA member ID!
Founded in 2006, Massachusetts-based biotechnology startup Gelesis has raised a total of $118.2 million for developing an oral smart pill. In 2016, the company initially filed an IPO offering of $60 million, but pulled out and instead focused on raising more funding. The technology is based on capsules filled with tiny hydrogel particles that expand between 50 to 100 times their weight in size after absorbing water from the stomach, which results in increased satiety to help obese diabetes patients lose weight and control their sugar metabolism. They are currently undergoing a phase 2 clinical trial on their Gelesis200 product for treating diabetes.
While there is currently no cure for diabetes, researchers are hopeful for advancements. A 2017 pilot study may provide hope for a diabetes cure in the future. Researchers found that an intensive metabolic intervention, combining personalized exercise routines, strict diet, and glucose-controlling drugs could achieve partial or complete remission in 40 percent of patients, who were then able to stop their medication. More comprehensive studies are in the pipeline.
A Wall Street Journal op-ed by Tommy Meyerson, a veteran of the Syria campaign, argues that “the Kurdish-led civil administration does the heavy lifting of guarding hundreds of ISIS’ most dangerous foreign fighters,” asserts that the West “owes them a debt,” and warns that a Turkish invasion into territory they hold “would force Kurdish forces to pull back from the front lines against the remnant of ISIS, allowing the jihadists to regroup and proliferate.”
Diabetes Relief provides the gold standard for diabetes care by employing its patent-pending protocol using FDA-approved drugs and devices that are covered and recognized by most insurance providers. Upon receipt of approval from Diabetes Relief, physicians can apply for affiliation to become a licensed Diabetes Healthcare Center. Assistance with all aspects of build-out of the care facility and hiring and training staff is provided to approved practices.
Type 1 diabetes is partly inherited, with multiple genes, including certain HLA genotypes, known to influence the risk of diabetes. In genetically susceptible people, the onset of diabetes can be triggered by one or more environmental factors, such as a viral infection or diet. Several viruses have been implicated, but to date there is no stringent evidence to support this hypothesis in humans. Among dietary factors, data suggest that gliadin (a protein present in gluten) may play a role in the development of type 1 diabetes, but the mechanism is not fully understood.
Diabetes mellitus is a group of metabolic diseases characterized by high blood sugar (glucose) levels that result from defects in insulin secretion, or its action, or both. Diabetes mellitus, commonly referred to as diabetes (as it will be in this article) was first identified as a disease associated with "sweet urine," and excessive muscle loss in the ancient world. Elevated levels of blood glucose (hyperglycemia) lead to spillage of glucose into the urine, hence the term sweet urine.
The fact these improvements can happen independently of weight loss should also signify a shift in how we conceptualize both obesity and diabetes, according to Peter Billings, the Seattle bariatric surgeon who operated on Benari. Billings, a nearly 20-year veteran in the field, has started to perform surgery on other lower-BMI patients similar to Benari, though they often pay out of pocket.
The problem, according to gastroenterologist Hiroshi Mashimo, MD, PhD, is that 70 percent of PPI users take the medications incorrectly. “They aren’t getting proper instruction,” says Mashimo. “Most people equate PPIs as a stronger form of an antacid.” Antacids neutralize acid and are meant to be taken to quell symptoms as they occur. PPIs are part of a more long-term strategy. The right way to take them is in the morning, just before or with breakfast. Food “turns on” the body’s acid-making cells; the medication can then work to stop stomach acid production.
Certain drugs may also help to control pain. These include anti-inflammatory medicines such as ibuprofen, aspirin, naproxen, indomethacin, and many others. While some of these are sold over the counter, they can have side effects, most notably gastrointestinal bleeding. A newer anti-inflammatory, celecoxib (Celebrex), may have fewer gastrointestinal side effects.
Currently, people with diabetes who receive a transplanted pancreas (typically not possible unless you are also having a kidney transplant) or who receive islet-cell transplants as part of a research study in the US must take these drugs so that their own body won’t attack the new cells. The drugs work, but raise risk for bacterial and viral infections as well as for mouth sores, nausea, diarrhea, high cholesterol, high blood pressure, fatigue and even some cancers.
I was diagnosed as a Type I diabetic in October 1993. I was traveling at the time, and I felt lethargic, I was always thirsty, and I was having trouble concentrating. When I returned home, I went for a checkup, and the doctor confirmed my condition. From that day forward, I’ve been injecting myself with insulin every day. Before I switched to an insulin pump in 2011, I calculated that I had given myself about 30,000 needles. That’s a lot of jabbing.
He asked and then demanded that the 200 or so chairs in the middle of the auditorium be rearranged. This required summoning the fire marshal (as the aisle was a matter of code) who insisted that no changes could be made. Brand held his ground. Event planners gathered around him trying to talk him down. Even if it weren’t for the fire code, moving the chairs at this point would have to be done by union workers and would take time. The audience was waiting outside baking in the sun, Hoess, Wanderlust’s CEO, reminded Brand. But he was insistent. I sensed he was willing to threaten to not go on at all when the organizers finally broke down and agreed to move the chairs.
For now, I manage my diabetes through a combination of technologies. I use a blood test meter to measure my glucose levels at least five times a day. I use a pump that is attached to my abdomen to deliver frequent doses of insulin throughout the day. And now I also use a continuous monitoring device that measures my subcutaneous blood sugar levels to help the insulin pump work more effectively.
Poxel (PP:POXEL) is a French pharmaceutical company that recently received $30.1 million in post-IPO equity in 2016. The company has developed an orally active medication called Imeglimin, which targets all three organs and body systems that are affected by diabetes simultaneously: the pancreas, liver, and muscles. The drug is currently undergoing phase 3 clinical work in Japan, and will commence phase 3 trials in the European Union and the United States that will be completed by 2019. The company is also concurrently working on several other pharmaceutical agents in various stages of the development pipeline.
According to Jack D. Bragg, DO, associate professor of clinical medicine at the University of Missouri, most diabetes-related GI issues stem from a problem with one thing: motion. The digestive tract is a finely tuned muscular machine. It pulls and pushes, expands and contracts, relaxes and squeezes to carry food from your mouth, down the esophagus, into the stomach, and, finally, through 25 feet of nutrient- and water-extracting intestine that ends in, well, your exit.